Glycogen-storage and carbohydrate metabolism disorders

The fellowship mark goes to the candidate who frames these disorders around one physiological idea and three clinical patterns. The idea is that glycogen is the liver's battery: it stores glucose between feeds and releases it as free glucose during fasting, and a defect anywhere along that release pathway starves the brain while the liver swells with the stored glycogen it cannot use. The first pattern is the hepatic energy-failure pattern — a child with a big liver, a low glucose, a high lactate and, in GSD I, the tell-tale urate and lipid rises. The second is the lysosomal muscle pattern of Pompe — a floppy baby with a thick heart. The third is the exercise-intolerance pattern of the muscle glycogenoses — a child or young adult who cramps and "warms up" into a second wind. Holding these three patterns together is what turns a confusing list of numbered diseases into a recognisable clinical framework. ^{[1] [7]}

Overview & Definition

The glycogen-storage and carbohydrate metabolism disorders are a family of inherited metabolic diseases in which the body cannot make, break down or correctly use stored glycogen or dietary sugars. The largest group, the glycogen storage diseases (GSDs, the glycogenoses), are numbered 0 to XIII by the enzyme or transporter affected, and they share a common biochemistry: a defect in the synthesis, breakdown or intracellular handling of glycogen that either starves the body of glucose during fasting or swells tissues with glycogen that cannot be processed. Alongside them sit the carbohydrate (sugar) metabolism disorders, in which a specific dietary sugar cannot be metabolised and its toxic intermediates accumulate. Classic galactosaemia from galactose-1-phosphate uridylyltransferase deficiency, hereditary fructose intolerance from aldolase B deficiency, and fructose-1,6-bisphosphatase deficiency. ^{[1] [12]}

The single most useful organising principle is where the block sits and which tissue it cripples. The hepatic, fuel-regulating enzyme defects — glycogen synthase (GSD 0), glucose-6-phosphatase and its translocase (GSD I), the debrancher enzyme (GSD III), liver phosphorylase (GSD VI) and phosphorylase kinase (GSD IX). All produce fasting hypoglycaemia because the liver cannot release free glucose. Pompe disease (GSD II) is biochemically different: acid α-glucosidase works inside the lysosome, so its deficiency floods the lysosome with glycogen and damages cardiac and skeletal muscle rather than blood glucose. The muscle glycogenoses (GSD V McArdle, GSD VII Tarui) block glycolysis within exercising muscle and produce exercise intolerance. Recognising these three clinical destinations — liver energy failure, lysosomal muscle disease, and exertional muscle pain — is the foundation of the whole topic. ^{[1] [5] [11]}

A fellow should leave this overview with a working definition, not a numbered list. A glycogen storage disease is an inherited defect of glycogen synthesis, breakdown or handling that produces a recognisable tissue-specific syndrome. Fasting energy failure in the liver, cardiomyopathy and hypotonia in the lysosome, or exercise intolerance in muscle. The carbohydrate metabolism disorders are the closely related group in which a dietary sugar cannot be metabolised, causing toxic-metabolite injury. The two groups are taught together because their presentation overlaps (hepatomegaly, hypoglycaemia, lactic acidosis), their investigation overlaps (the fasting metabolic panel), and. Critically — their management overlaps in the principle of preventing the metabolic stress that unmasks the enzyme block. ^{[1] [7]}

References16ShowHide

1. [1]Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GPA. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr, 2002.PMID 12373584
2. [2]Weinstein DA, Wolfsdorf JI Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr, 2002.PMID 12373568
3. [3]Matern D, Seydewitz HH, Bali D, Lang C, Chen YT. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr, 2002.PMID 12373566
4. [4]Sim SW, Weinstein DA, Lee YM, et al. Glycogen storage disease type Ib: role of glucose-6-phosphate transporter in cell metabolism and function. FEBS Lett, 2020.PMID 31705665
5. [5]Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med, 2006.PMID 16702877
6. [6]Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol, 2021.PMID 34800400
7. [7]Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med, 2010.PMID 20631546
8. [8]Sentner CP, Hoogeveen IJ, Weinstein DA, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis, 2016.PMID 27106217
9. [9]Kishnani PS, Goldstein J, Austin SL, Arn P, Bachrach B, Bali DS, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 2019.PMID 30659246
10. [10]Koch RL, Soler-Alfonso C, Kiely BT, et al. Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: a clinical practice resource. Mol Genet Metab, 2023.PMID 36796138
11. [11]Lucia A, Martinuzzi A, Nogales-Gadea G, et al. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord, 2021.PMID 34848128
12. [12]Van Calcar SC, Bernstein LE, Rohr FJ, et al. A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. Mol Genet Metab, 2014.PMID 24857409
13. [13]Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet, 1998.PMID 9610797
14. [14]Yi C. Fructose-1,6-bisphosphatase deficiency. Endokrynol Pol, 2022.PMID 35971930
15. [15]Boers SJ, Visser G, Smit PG, Fuchs SA. Liver transplantation in glycogen storage disease type I. Orphanet J Rare Dis, 2014.PMID 24716823
16. [16]Koeberl DD, Koch RL, Lim JA, et al. Gene therapy for glycogen storage diseases. J Inherit Metab Dis, 2024.PMID 37421310